Evidence map›Paper›PMID 31520111›Full record

ArticleWorld journal of urology2020

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.

Johannes Heide, Silvia Ribback, Tobias Klatte, Shahrokh Shariat, Martin Burchardt, Frank Dombrowski, Arie S Belldegrun, Alexandra Drakaki, Allan J Pantuck, Nils Kroeger

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johannes HeideDepartment of Urology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, F. Sauerbruch Str, 17475, Greifswald, Germany.
Silvia RibbackInstitute of Pathology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.
Tobias KlatteDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Shahrokh ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Martin BurchardtDepartment of Urology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, F. Sauerbruch Str, 17475, Greifswald, Germany.
Frank DombrowskiInstitute of Pathology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.
Arie S BelldegrunDepartment of Urology at the David Geffen-School of Medicine, Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Alexandra DrakakiDepartment of Urology at the David Geffen-School of Medicine, Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Allan J PantuckDepartment of Urology at the David Geffen-School of Medicine, Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Nils KroegerDepartment of Urology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, F. Sauerbruch Str, 17475, Greifswald, Germany. md.nkroeger@gmail.com.ORCID http://orcid.org/0000-0001-6659-1374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCo-morbidities may induce local and systemic tumor progression of renal cell carcinoma (RCC); however, the prognostic impact of co-morbidities has not yet been well characterized. PATIENTS AND

methodsRCC patients (n = 2206) surgically treated at three academic institutions in the US and Europe were included in the analysis. Presence of diabetes mellitus, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, coronary heart disease, and hypothyroidism were investigated for their association with clinicopathological features and cancer-specific survival.

resultsHypertension was associated with less advanced T stages (p = 0.025), a lower risk of lymph-node (p = 0.026) and distant metastases (p = 0.001), and improved cancer specific survival in univariable analysis (HR 0.81 95% CI 0.69-0.96, p = 0.013). However, hypertension was not an independent prognostic factor after adjustment for TNM stages, grading, and ECOG performance status (HR 0.95, 95% CI 0.80-1.12; p = 0.530). A correlation between the use of concomitant anti-hypertensive medications and improved survival outcome was not identified. All other investigated co-morbidities did not show significant associations with clinicopathological features or cancer-specific survival.

conclusionAlthough the investigated co-morbidities are capable or inducing pathophysiological changes that are predisposing factors for tumor progression, none is an independent prognostic factor in patients with RCC.

Indexed as

AgedCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTreatment OutcomeAnti-hypertensive medicationCo-morbiditiesHypertensionPrognostic factorsRenal cell carcinomaStatins

Identifiers

PMID31520111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.